[4] Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion.

[2][6][7] Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

[15] That same year, Apotex acquired Lareq Pharma SL of Spain from Industria Quimica Y Farmaceutica to extend the company's presence in Western Europe.

[19] On Friday, December 15, 2017, Apotex founder Barry Sherman and his wife Honey were discovered murdered at their home in North York.

[21] "In June 2018, a lower court judge issued an order protecting the files, which concern the appointment of estate trustees and would ordinarily be available for public inspection.

In this situation, Apotex would be able to bring to market a generic version of Plavix, even before the expiration of Sanofi-Aventis SA and Bristol-Myers Squibb's patent on the drug.

"[23][24] In 2013, Apotex began selling a biosimilar version of Amgen's Neulasta in Europe, a blockbuster drug used by cancer patients in chemotherapy as a way to boost white blood count.

[27] The closing of Apotex Pharmaceutical Holdings Inc.'s acquisition by an affiliate of investors advised by SK Capital Partners was announced on April 3, 2023.

Cangene's business focuses are hyperimmune drugs, contract manufacturing, biopharmaceuticals and biodefense against infectious diseases such as smallpox, hepatitis B and anthrax.

In September 2014, in response to the spread of the chikungunya virus in Haiti, Apotex worked with the humanitarian organization Direct Relief to donate more than $2.2 million in medical aid to the country.

[36] In September 2008, after four years of fighting "a morass of red tape and petty politics", Apotex shipped seven million doses of Apo-TriAvir, the generic AIDS medication that resulted from the research, to Rwanda.

[14] In a 2008 article on pharmaceutical patent cases, The Globe and Mail cited Apotex as being "prepared to wage expensive courtroom battles with the help of high-priced talent from such firms as Goodmans LLP".

[39] In a 2007 National Post article, Apotex revealed that it spent roughly $60-million a year on legal fees, both in defense of the company and working toward expanding the number of generics on the market.

In the filing, Apotex cited unfair treatment by FDA which constituted a violation of the North American Free Trade Agreement (NAFTA).

[47] In 2020, the US DOJ fined Apotex $24,100,000 for colluding with other pharmaceutical companies to price fix—raising costs of vital drugs for users who needed its cholesterol medicine.

In the words of Special Agent in Charge Scott Pierce: "When generic drug companies conspire to fix prices and rig bids, they do so to the detriment of many who depend on these medications to maintain good health".

[48] In the words of U.S. Attorney William M. McSwain, "Compromising the health and welfare of innocent people by artificially inflating the price of a much needed medication is not only morally wrong, but illegal.

[48] On October 31, 2024, Apotex and Heritage Pharmaceuticals agreed to pay $49.1 million to resolve allegations of price-fixing in collusion to artificially raise drug prices as charged by a coalition of 50 U.S. state attorneys general.

"[52] On 17 May 2013, a group of pregnant Canadian women filed a class-action lawsuit against Apotex, after it was discovered that the company's recalled birth control pill packages contained more placebos than usual.

[56] In April 2015, the Supreme Court of Canada (SCC) affirmed the FCA's section 8 quantification decision with respect to the litigation between Sanofi and Apotex.

[56] In October 2014, Apotex filed a lawsuit against the Canadian government to overturn a ban on importing drugs manufactured in its overseas (India) factories.

[57] In 2021, Bayer and Viatris' Meda Pharmaceuticals filed a lawsuit against Apotex to delay FDA approval of the company's generic version of Astepro Allergy nasal spray, alleging patent infringement.